louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06444503: Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies
Official title: Creation of a Biological Collection to Study the Pathophysiology and Identify Predictive Factors for the Evolution of Bone, Calcium and Growth Plate Pathologies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bone Disorder
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2024-06-05
Enrollment: 350
Sex: ALL
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with with growth plate or bone pathology.

Brief summary: The aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies.

This collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.


Eligibility criteria: Inclusion Criteria:

* Children (from birth) with growth plate or bone pathology
* Patients affiliated to or benefiting from a social security scheme
* Patients able to receive information about the study and to understand the information form in order to participate in the study. This implies :
* mastery of the French language
* Not being subject to a restriction of rights by the judicial authorities
* Patients or legal representatives having given their consent to participate in the study (expression of non-opposition).

Exclusion Criteria:

* Patients under legal protection (guardianship, curatorship or safeguard of justice)
* Pregnant or breast-feeding women

Primary outcomes:
measure: Building a collection of biological samples and clinical-biological data from patients presenting bone, calcium and growth plate pathologies
timeFrame: Day 0 and through study completion, an average of 5 years
Secondary outcomes:
measure: Identification of potential markers of disease progression based on new knowledge.
timeFrame: Day 0 and through study completion, an average of 5 years
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Toulouse Hospital
Study officials:
affiliation: CHU Toulouse
name: Thomas EDOUARD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06974903: Retrospective Observational Study on GERD Management in General Hospitals in Korea
Official title: A RetrospectiVe ObservatIoNal Study of a CurrEnt Status and Its Management of GERD (GastroEsophageal Reflux Disease) in General HOspitals in Korea
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastroesophageal Reflux Disease (GERD)
Keywords: GastroEsophageal Reflux Disease
GERD
Korean patients
Observational study
RetrospectiVe Observational study
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2025-05-16
Enrollment: 13750
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with Gastroesophageal Reflux Disease(GERD)

Brief summary: A RetrospectiVe ObservatIoNal Study of a CurrEnt Status and its Management of GERD (GastroEsophageal Reflux Disease) in General HOspitals in Korea

Detailed description: This study is designed as a multicenter, retrospective observational study. After signing a contract with the research institution or investigator, patients who meet the inclusion/exclusion criteria in the study protocol will be enrolled. The registration of patients at each research site will be carried out in order based on the most recent visit date (or GERD diagnosis date) as of January 1, 2018. Data from the study subjects will be collected by reviewing medical records from January 1, 2018, to August 31, 2020. These data will be recorded in the eCRF through interviews, examinations, and tests performed under the investigator's judgment during routine clinical practice within this period.

Eligibility criteria: Inclusion Criteria:

1. Patients aged 19 years or older as of the date of their first visit.
2. Patients who visited domestic general hospitals (secondary and tertiary healthcare institutions) at least twice between January 1, 2018, and August 31, 2020, for the diagnosis or treatment of GERD.

Exclusion Criteria:

1. Patients with no GERD treatment information recorded in the medical records, even once.
2. Patients deemed inappropriate for participation by the investigator (e.g., when the overall GERD diagnosis/treatment information is missing from the medical records).

Primary outcomes:
measure: Evaluation of Incidence of Adverse events following the administration of GERD treatment medications
timeFrame: From enrollment to 2 years and 7 months after registration
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hanyang University Hospital
state: Seongdong-gu
Study officials:
References:
Clinical trial NCT01390103: Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain
Official title: Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Pain
Keywords: hip pain
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2011-07-08
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Potential subjects will be all patients receiving a hip injection for hip pain.

Brief summary: The purpose of this project is to determine the effect of hip injections on hip biomechanics in patients with hip pain.


Eligibility criteria: Inclusion Criteria:

* Osteoarthritis patients with hip pain requiring hip injection
* Receiving hip injection
* BMI \< 35

Exclusion Criteria:

* BMI \> 35
* severely impaired intellectual capacity
* dementia, or other neurodegenerative diseases that would preclude appropriate cognitive or physical ability to perform study protocol

Primary outcomes:
measure: Determine the immediate biomechanical effect in patients that receive a hip injection.
timeFrame: The short-term biomechanical effects of the hip will be evaluated within 1 hour of the patient receiving the injection.
Secondary outcomes:
measure: Oswestry Hip Pain Disability Questionnaire
timeFrame: Baseline, Within 1 hour of hip injection, 2 weeks post-injection
measure: Medical Outcomes Study (MOS) Short-Form Health Survey (SF-12)
timeFrame: Baseline, Within 1 hour of injection, 2 weeks post-injection
measure: 10 centimeter Visual Analog Scale (VAS)
timeFrame: Baseline, Within 1 hour of injection, 2 weeks post-injection
measure: Pain Provocative Maneuvers
timeFrame: Baseline, Within 1 hour of injection, 2 weeks pos-injection
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: UF&Shands Orthopaedics and Sports Medicine Institute
state: Florida
Study officials:
affiliation: University of Florida Departmen of Orthopaedics
name: MaryBeth Horodyski, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01378403: Evaluation of Dorsal Visual Stream in Patients With Schizophrenia
Official title: Evaluation of Dorsal Visual Stream in Patients With Schizophrenia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Keywords: Schizophrenia
Cognitive deficites
Degraded objects
Magnocellular pathway
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-06-22
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from schizophrenia

Brief summary: Schizophrenia patients in comparing to normal controls show decreased ability to identify objects with decreased level of fragmentation, a task that is associated with magnocellular pathway function.


Eligibility criteria: Inclusion Criteria:

* Schizophrenia

Exclusion Criteria:

* Ophthalomological or Neurological problems
* Left handed

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat-Gan
country: Israel
facility: Psychiatry Clinic - Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Revital Amiaz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04727203: Active and Healthy Ageing for All: a Multi-component Healthy Lifestyle Program
Official title: Active and Healthy Ageing for All: a Multi-component Healthy Lifestyle Program (AHAA)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Health Promotion
Keywords: ageing
healthy lifestyle
intervention
Lead sponsor: KU Leuven
Sponsor class: OTHER
Collaborators: name: Odisee University college for applied sciences
First posted: 2021-01-27
Enrollment: 400
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: There are 6 groups in this intervention
Primary purpose: BASIC_SCIENCE

Brief summary: AHAA is a healthy lifestyle program offered to older adults aged 60+ years. The program is developed based upon co-creation with the target group and implemented and evaluated in several locations.

Detailed description: 1. co-creation : all participants will be questioned and included in the co-creation session
2. implementation : the developed multicomponent healthy lifestyle program will be enrolled and implemented in 6 locations (community services for older adults in Flanders and Brussels)
3. evaluation : the program will be evaluated (effects and process)

Eligibility criteria: Inclusion Criteria:

* age 60+ years

Exclusion Criteria:

* not being able to attend the weekly meetings

Primary outcomes:
measure: Physical activity measured by IPAQ
timeFrame: up to twelve weeks
measure: Physical activity measured by accelerometry
timeFrame: up to twelve weeks
measure: Sedentary behaviour measured by accelerometry
timeFrame: up to twelve weeks
measure: Sedentary behaviour measured by IPAQ
timeFrame: up to twelve weeks
measure: Nutrition questionnaire (self-reported)
timeFrame: up to twelve weeks
measure: Sleep measured by accelerometry
timeFrame: up to twelve weeks
measure: Sleep measured by PSQI
timeFrame: up to twelve weeks
Secondary outcomes:
measure: well-being measured by WEMWBS
timeFrame: up to twelve weeks
measure: Perceived stress measured by the perceived stress scale
timeFrame: up to twelve weeks
measure: Perceived positive health status measured by a self-reported questionnaire
timeFrame: up to twelve weeks
measure: Health literacy measured by HLSQ self-reported questionnaire
timeFrame: up to twelve weeks
measure: Social support measured by a self-reported questionnaire
timeFrame: up to twelve weeks
Other outcomes:
Locations:
city: Aalst
country: Belgium
facility: LDC
city: Brussel
country: Belgium
facility: LDC
city: Gent
country: Belgium
facility: Regie Ouderenzorg
city: Mechelen
country: Belgium
facility: LDC
city: Sint-Truiden
country: Belgium
facility: Triamant
Study officials:
affiliation: KU Leuven
name: Julie Vanderlinden, PHDc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02983903: Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions
Official title: An Un-blinded, Intra-patient Comparison of Transbronchial Forceps Biopsy and Cryobiopsy for Peripheral Pulmonary Lesions
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Solitary Pulmonary Nodule
Multiple Pulmonary Nodules
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Andrew Haas
name: Anil Vachani
name: Anthony Lanfranco
name: Kevin Ma
name: Jeffrey Thompson
name: Edmund Moon
First posted: 2016-12-06
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Purpose: Patients with peripheral lung nodules require evaluation for lung cancer. Our aim is to assess the diagnostic yield of a new technique, transbronchial cryobiopsies, in patients at risk for lung cancer. Target population: Patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions. Procedures: Patients enrolled will have forceps transbronchial biopsies followed by transbronchial cryobiopsies for their lung lesion during bronchoscopy.


Eligibility criteria: Inclusion Criteria:

1. Age \>/= 18
2. At least one peripheral lung lesion \>8mm documented on CT scan referred for diagnostic bronchoscopy
3. Subject is able to undergo informed consent

Exclusion Criteria:

1. Coagulopathy (platelet count \< 50,000, INR \> 1.5) detected on blood testing done within 6 weeks of the procedural visit
2. Lesion associated with a prominent vessel evident on CT scan
3. Pure ground glass lesion
4. Fibrotic interstitial lung abnormalities on chest CT
5. Bullous emphysema in region of nodule
6. Supplemental oxygen utilization at baseline
7. BMI \> 40
8. End stage renal disease

Primary outcomes:
measure: The increase in sensitivity for diagnosing lung cancer with the addition of cryobiopsy to standard forceps biopsy for a suspicious lung nodule.
timeFrame: 1 year
Secondary outcomes:
measure: The increase in sensitivity for diagnosing a specific benign lung disease with the addition of cryobiopsy to standard forceps biopsy for a suspicious lung nodule.
timeFrame: 1 year
measure: The number of participants with pneumothorax or significant bleeding related to the addition of transbronchial cryobiopsy to standard forceps biopsy.
timeFrame: 1 year
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennslyvania
name: David M DiBardino, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04861103: Anticoagulation Profile in Pregnant Women Treated with Three Times a Day of Low Molecular Weight Heparin (LMWH)
Official title: Anticoagulation Profile in Pregnant Women Treated with Three Times a Day of Low Molecular Weight Heparin (LMWH)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Pregnancy, High Risk
Anticoagulants
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2021-04-27
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Pregnancy is associated with a increased risk of developing blood clots. There is nearly a 5 times greater risk of developing a blood clot in pregnancy. Lovenox is a medication that helps to prevent the body from developing clots. It is safe to use in pregnancy. Previous studies have demonstrated that despite recommendation of Lovenox, to prevent blood clots, the majority of patient's (70 to 90%) did not receive adequate levels of Lovenox at times throughout the day, which likely increases the risk of developing clots. The increase in blood volume and increase in kidney function that occurs in pregnancy may contribute to the inadequate levels. Currently the recommendation for pregnant and nonpregnant patients requiring Lovenox, is to calculate the daily dose of Lovenox and split the dose, giving half in the morning and the other half in the evening. This research study proposes that due to changes in the body during pregnancy that the daily Lovenox dosing be split into three times a day to achieve more consistent levels of Lovenox than twice a day in pregnant women.


Eligibility criteria: Inclusion Criteria:

* Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
* Participants must be age 18 or older.

Exclusion Criteria:

* Women with multiples.
* Women less than age 18
* History of Heparin Induced Thrombocytopenia (HIT)
* Allergy to enoxaparin

Primary outcomes:
measure: Factor Xa levels
timeFrame: 4 hours after injection
Secondary outcomes:
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California Irvine
state: California
Study officials:
affiliation: University of California, Irvine
name: Afshan Hameed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02216903: Respiratory Motion Related Ablation Gap and Clinical Outcome After Catheter Ablation for Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation, sleep apnea
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-08-15
Enrollment: 510
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients with atrial fibrillation who undergoing catheter ablation in Yonsei Cardiovascular hospital, Yonsei university health system, Seoul, Korea.

Brief summary: This is the evaluation which is associated with apnea symptom, one of the recurrence factors, after AF ablation to patients who diagnosed AF.

This is the evaluation which is associated with excessive respiration exercise during AF ablation to patients who diagnosed AF.

This is the evaluation which is associated with excessive respiration exercise to make a gap during AF ablation to patients who diagnosed AF.


Eligibility criteria: Inclusion Criteria:

1. age 20\~80
2. Left atrium size \<55mm

Exclusion Criteria:

1. Permeant AF which is uncontrolled by cardioverting
2. Valvular AF (mitral stenosis\> grade 2, mitral valvuloplasty)
3. Structural heart disease which is necessary operation to be healed.
4. The patients who had history of ablation or maze operation
5. The patients who have abnormal respiration by spinal or chest modification.
6. accompany Severe disease in present
7. Under age \<20

Primary outcomes:
measure: Clinical recurrence of atrial fibrillation (AF) after catheter ablation
timeFrame: after 90 days of catheter ablation and thereafter
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT04935203: Consumers' Emotional Reaction to Sustainability Cue
Official title: Can we Prime Sustainable Food Choice? A Mix-methods Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sustainable Food Consumption
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2021-06-22
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This will be a randomized control trial (RCT) to examine whether the three priming interventions (health priming, environmental sustainability priming, and co-benefits priming) work to change consumers' sustainable food choice through their effects on changing consumers' emotional reaction when seeing foods with cues of environmental sustainability, which will be indicated by measuring consumers' facial expression, eye movement and pupil dilation.


Eligibility criteria: Inclusion Criteria:

* Subjects should be aged 18 years or above
* Subjects should be Hong Kong residents
* Subjects should be able to read Chinese

Exclusion Criteria:

* Subjects who have vegan or vegetarian diets will be excluded
* Subjects who have to follow special diets due to illnesses will be excluded
* Subjects domestic helpers will also be excluded

Primary outcomes:
measure: Participants' choice of sustainable foods
timeFrame: Immediately after they are exposed to priming manipulation
measure: Participants' facial expression
timeFrame: Immediately after they are exposed to priming manipulation
measure: Participants' eye movement data
timeFrame: Immediately after they are exposed to priming manipulation
Secondary outcomes:
measure: Social orientation value
timeFrame: Immediately after they complete the computerized task with priming manipulation
measure: Pro-environmental values
timeFrame: Immediately after they complete the computerized task with priming manipulation
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Jockey Club Tower
Study officials:
References:
Clinical trial NCT06263803: The Effect of Listening to Music on Chronic Low Back Pain
Official title: The Effect of Passive Music Listening in Addition to Physical Therapy on Pain, Anxiety and Quality of Life in Patients With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Chronic
Lead sponsor: KTO Karatay University
Sponsor class: OTHER
First posted: 2024-02-16
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effects of passive music listening on pain, anxiety and quality of life in patients with chronic low back pain in addition to physical therapy will be examined.

Detailed description: The aim of the study was to investigate the effects of passive music listening in addition to physical therapy on pain, anxiety and quality of life in patients with chronic low back pain.There is no study in the literature examining the relationship between music listening and physical therapy in chronic back pain. Since our study will be the first to investigate the subject, we foresee that it is scientifically important and will shed light on future studies. In addition, national or international publications are planned after the study is completed.

Eligibility criteria: Inclusion Criteria:

patients with LBP for more than 3 months with pain severity of 5 or greater according to the visual analogue scale (VAS)

Exclusion Criteria:

individuals who regularly take painkillers or anti-depressant and cortisone; pregnant individuals; and individuals having severe chronic illness and spine surgery were excluded from the study

Primary outcomes:
measure: Beck anxiety inventory
timeFrame: baseline and 4 weeks
measure: Visual Analogue Scale
timeFrame: baseline and 4 weeks
measure: Short From-36
timeFrame: baseline and 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Karatay
country: Turkey
facility: Mustafa Savaş Torlak
state: Eyalet/Yerleşke
Study officials:
References: